RE-MIND2

• Research type

  Research Study

• Full title

  An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare outcomes to those from Tafasitamab + Lenolidomide in the L-MIND study

• IRAS ID

  278317

• Contact name

  Sabine Apelt

• Contact email

  sabine.apelt@morphosys.com

• Sponsor organisation

  MorphoSys AG

• Duration of Study in the UK

  0 years, 9 months, 30 days

• Research summary

  The aim of the study is to collect data on relapsed/refractory Diffuse large B cell Lymphoma (DLBCL) patients who have previously had at least two systemic treatments for their disease. The data collected is all historical and would be available in the participants medical notes. No further tests, no interviews, no additional activity is required from the participants.
  This data will then be used to "match" against individual DLBCL patients in a different study called L-MIND who were treated with lenolidamide and the experimental drug of the Sponsor - tafasitamab. This will allow a comparison of the experimental treatment with the efficacy of treatments given in routine clinical care.

• REC name

  Wales REC 1

• REC reference

  20/WA/0077

• Date of REC Opinion

  12 Mar 2020

• REC opinion

  Further Information Favourable Opinion